article

1. Biomarker-based staging of Alzheimer disease: rationale and clinical applications..  Nature reviews. Neurology.  20:232-244. 2024
2. Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis..  The Lancet. Neurology.  23:168-177. 2024
3. Spatial transcriptomic patterns underlying amyloid-β and tau pathology are associated with cognitive dysfunction in Alzheimer's disease..  Cell reports.  43:-. 2024
4. TAF15 amyloid filaments in frontotemporal lobar degeneration..  Nature.  625:345-351. 2023
5. BrainAGE Estimation: Influence of Field Strength, Voxel Size, Race, and Ethnicity..  medRxiv : the preprint server for health sciences.  2023
6. Associations Between Social Network Characteristics and Brain Structure Among Older Adults..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  20:1406-1420. 2023
7. Edge time series components of functional connectivity and cognitive function in Alzheimer's disease..  Brain imaging and behavior.  18:243-255. 2023
8. Edge Time Series Components of Functional Connectivity and Cognitive Function in Alzheimer's Disease..  medRxiv : the preprint server for health sciences.  2023
9. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics..  Brain : a journal of neurology.  146:4414-4424. 2023
10. The Sporadic Early-onset Alzheimer's Disease Signature Of Atrophy: Preliminary Findings From The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) Cohort..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19 Suppl 9:S74-S88. 2023
11. Pathogenic variants in the Longitudinal Early-onset Alzheimer's Disease Study cohort..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19 Suppl 9:S64-S73. 2023
12. Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer's Disease Study (LEADS)..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19 Suppl 9:S98-S114. 2023
13. The relationship between learning slopes and Alzheimer's Disease biomarkers in cognitively unimpaired participants with and without subjective memory concerns..  Journal of clinical and experimental neuropsychology.  45:1-17. 2023
14. Influence of amyloid and diagnostic syndrome on non-traditional memory scores in early-onset Alzheimer's disease..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19 Suppl 9:S29-S41. 2023
15. Spatial transcriptomic patterns underlying regional vulnerability to amyloid-β and tau pathologies and their relationships to cognitive dysfunction in Alzheimer's disease..  medRxiv : the preprint server for health sciences.  2023
16. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial..  JAMA.  330:512-527. 2023
17. Sex and APOE ε4 carrier effects on atrophy, amyloid PET, and tau PET burden in early-onset Alzheimer's disease..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19 Suppl 9:S49-S63. 2023
18. Cerebrospinal fluid biomarkers in the Longitudinal Early-onset Alzheimer's Disease Study..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19 Suppl 9:S115-S125. 2023
19. White matter hyperintensities are higher among early-onset Alzheimer's disease participants than their cognitively normal and early-onset nonAD peers: Longitudinal Early-onset Alzheimer's Disease Study (LEADS)..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19 Suppl 9:S89-S97. 2023
20. GRB14.  medRxiv : the preprint server for health sciences.  2023
21. A simulative deep learning model of SNP interactions on chromosome 19 for predicting Alzheimer's disease risk and rates of disease progression..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19:5690-5699. 2023
22. Developments in understanding early onset Alzheimer's disease..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19 Suppl 9:S126-S131. 2023
23. Amyloid and tau pathology are associated with cerebral blood flow in a mixed sample of nondemented older adults with and without vascular risk factors for Alzheimer's disease..  Neurobiology of aging.  103-113. 2023
24. Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19 Suppl 9:S42-S48. 2023
25. Profiling baseline performance on the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collection..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19 Suppl 9:S8-S18. 2023
26. Accelerating diversity in Alzheimer's disease research by partnering with a community advisory board..  Alzheimer's & dementia (New York, N. Y.).  9:-. 2023
27. Learning slopes in early-onset Alzheimer's disease..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19 Suppl 9:S19-S28. 2023
28. Social enrichment on the job: Complex work with people improves episodic memory, promotes brain reserve, and reduces the risk of dementia..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19:2655-2665. 2023
29. CYP1B1-RMDN2.  medRxiv : the preprint server for health sciences.  2023
30. APOE ε4 is associated with earlier symptom onset in LOAD but later symptom onset in EOAD..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19:2212-2217. 2023
31. Neuroimaging in Dementia..  Continuum (Minneapolis, Minn.).  29:219-254. 2023
32. Association of Brain Volume and Retinal Thickness in the Early Stages of Alzheimer's Disease..  Journal of Alzheimer's disease : JAD.  91:743-752. 2023
33. Criterion Validation of Tau PET Staging Schemes in Relation to Cognitive Outcomes..  Journal of Alzheimer's disease : JAD.  96:197-214. 2023
34. Lecanemab: Appropriate Use Recommendations..  The journal of prevention of Alzheimer's disease.  10:362-377. 2023
35. Altered cerebral blood flow in older adults with Alzheimer's disease: a systematic review..  Brain imaging and behavior.  17:223-256. 2022
36. APOE ε4 carrier status and sex differentiate rates of cognitive decline in early- and late-onset Alzheimer's disease..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  19:1983-1993. 2022
37. Sensitivity of memory subtests and learning slopes from the ADAS-Cog to distinguish along the continuum of the NIA-AA Research Framework for Alzheimer's Disease..  Neuropsychology, development, and cognition. Section B, Aging, neuropsychology and cognition.  30:1-19. 2022
38. Designing the next-generation clinical care pathway for Alzheimer's disease..  Nature aging.  2:692-703. 2022
39. Social Networks and Cognitive Reserve: Network Structure Moderates the Association Between Amygdalar Volume and Cognitive Outcomes..  The journals of gerontology. Series B, Psychological sciences and social sciences.  77:1490-1500. 2022
40. Validation of and Demographically Adjusted Normative Data for the Learning Ratio Derived from the RAVLT in Robustly Intact Older Adults..  Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.  37:981-993. 2022
41. Social Networks and Cognitive Function: An Evaluation of Social Bridging and Bonding Mechanisms..  The Gerontologist.  62:865-875. 2022
42. Assessing and validating reliable change across ADNI protocols..  Journal of clinical and experimental neuropsychology.  44:85-102. 2022
43. Hippocampal-subfield microstructures and their relation to plasma biomarkers in Alzheimer's disease..  Brain : a journal of neurology.  145:2149-2160. 2022
44. Atypical Alzheimer Disease Variants..  Continuum (Minneapolis, Minn.).  28:676-701. 2022
45. Do subjective or objective cognitive measures better predict social network type among older adults?.  Biodemography and social biology.  67:1-14. 2022
46. Virtual reality cognitive intervention for heart failure: CORE study protocol..  Alzheimer's & dementia (New York, N. Y.).  8:-. 2022
47. Examining the role of repeated test exposure over 12 months across ADNI protocols..  Alzheimer's & dementia (Amsterdam, Netherlands).  14:-. 2022
48. Alzheimer's disease research progress in the Mediterranean region: The Alzheimer's Association International Conference Satellite Symposium..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  18:1957-1968. 2022
49. Characterization of gene expression patterns in mild cognitive impairment using a transcriptomics approach and neuroimaging endophenotypes..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  18:2493-2508. 2022
50. Cognitively stimulating environments and cognitive reserve: the case of personal social networks..  Neurobiology of aging.  197-203. 2022
51. Associations between Cortical Thickness and Metamemory in Alzheimer's Disease..  Brain imaging and behavior.  16:1495-1503. 2022
52. Aducanumab: Appropriate Use Recommendations Update..  The journal of prevention of Alzheimer's disease.  9:221-230. 2022
53. Measuring Subjective Cognitive Decline in Older Adults: Harmonization Between the Cognitive Change Index and the Measurement of Everyday Cognition Instruments..  Journal of Alzheimer's disease : JAD.  87:761-769. 2022
54. Why the cognitive "fountain of youth" may be upstream: Pathways to dementia risk and resilience through social connectedness..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  18:934-941. 2021
55. Head injury is associated with tau deposition on PET in MCI and AD patients..  Alzheimer's & dementia (Amsterdam, Netherlands).  13:-. 2021
56. Predicting the Emergence of Major Neurocognitive Disorder Within Three Months After a Stroke..  Frontiers in aging neuroscience.  -. 2021
57. Treatment Challenges and the Hope of Emerging Therapies in Early-Stage Alzheimer Disease..  The Journal of clinical psychiatry.  82. 2021
58. Differential effects of risk factors on the cognitive trajectory of early- and late-onset Alzheimer's disease..  Alzheimer's research & therapy.  13:-. 2021
59. Temporal stability of the ventral attention network and general cognition along the Alzheimer's disease spectrum..  NeuroImage. Clinical.  -. 2021
60. The Longitudinal Early-onset Alzheimer's Disease Study (LEADS): Framework and methodology..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  17:2043-2055. 2021
61. Talking With Patients and Care Partners About Treatment Goals and Challenges in Early-Stage Alzheimer Disease..  The Journal of clinical psychiatry.  82. 2021
62. Optimizing differential identifiability improves connectome predictive modeling of cognitive deficits from functional connectivity in Alzheimer's disease..  Human brain mapping.  42:3500-3516. 2021
63. Early-Stage Alzheimer Primer: Pathophysiology, Diagnosis, and Assessment..  The Journal of clinical psychiatry.  82. 2021
64. Donanemab in Early Alzheimer's Disease..  The New England journal of medicine.  384:1691-1704. 2021
65. New insights into atypical Alzheimer's disease in the era of biomarkers..  The Lancet. Neurology.  20:222-234. 2021
66. Aducanumab: Appropriate Use Recommendations..  The journal of prevention of Alzheimer's disease.  8:398-410. 2021
67. Tau-related white-matter alterations along spatially selective pathways..  NeuroImage.  -. 2020
68. Genome-wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  16:1213-1223. 2020
69. Neurodegenerative changes in early- and late-onset cognitive impairment with and without brain amyloidosis..  Alzheimer's research & therapy.  12:-. 2020
70. Testing influences of APOE and BDNF genes and heart failure on cognitive function..  Heart & lung : the journal of critical care.  50:51-58. 2020
71. Neurodegenerative Patterns of Cognitive Clusters of Early-Onset Alzheimer's Disease Subjects: Evidence for Disease Heterogeneity..  Dementia and geriatric cognitive disorders.  48:131-142. 2020
72. Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: a multisite observational cohort study..  BMJ open.  9:-. 2019
73. Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson's disease..  NPJ Parkinson's disease.  -. 2019
74. Epigenome-wide meta-analysis of blood DNA methylation and its association with subcortical volumes: findings from the ENIGMA Epigenetics Working Group..  Molecular psychiatry.  26:3884-3895. 2019
75. Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition..  Alzheimer's & dementia (Amsterdam, Netherlands).  510-519. 2019
76. The Functional Ability of MCI and Alzheimer's Patients Predicts Caregiver Burden..  GeroPsych.  32:31-39. 2019
77. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing..  Nature genetics.  51:414-430. 2019
78. Volumetric comparison of hippocampal subfields extracted from 4-minute accelerated vs. 8-minute high-resolution T2-weighted 3T MRI scans..  Brain imaging and behavior.  12:1583-1595. 2018
79. Associations of the Top 20 Alzheimer Disease Risk Variants With Brain Amyloidosis..  JAMA neurology.  75:328-341. 2018
80. Patient and Caregiver Assessment of the Benefits From the Clinical Use of Amyloid PET Imaging..  Alzheimer disease and associated disorders.  32:35-42. 2018
81. Associations between hippocampal morphometry and neuropathologic markers of Alzheimer's disease using 7 T MRI..  NeuroImage. Clinical.  56-61. 2017
82. Building a Surface Atlas of Hippocampal Subfields From High Resolution T2-weighted MRI Scans Using Landmark-free Surface Registration..  The ... Midwest Symposium on Circuits and Systems conference proceedings : MWSCAS. Midwest Symposium on Circuits and Systems.  2017
83. Tau Imaging in Alzheimer's Disease Diagnosis and Clinical Trials..  Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.  14:62-68. 2017
84. The effect of the top 20 Alzheimer disease risk genes on gray-matter density and FDG PET brain metabolism..  Alzheimer's & dementia (Amsterdam, Netherlands).  53-66. 2016
85. Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care..  Alzheimer's & dementia (Amsterdam, Netherlands).  15-22. 2016
86. A comparison of theoretical and statistically derived indices for predicting cognitive decline..  Alzheimer's & dementia (Amsterdam, Netherlands).  171-181. 2016
87. Novel verbal fluency scores and structural brain imaging for prediction of cognitive outcome in mild cognitive impairment..  Alzheimer's & dementia (Amsterdam, Netherlands).  113-22. 2016
88. Plasma BDNF levels associate with Pittsburgh compound B binding in the brain..  Alzheimer's & dementia (Amsterdam, Netherlands).  1:187-193. 2015
89. Clinical, FDG and amyloid PET imaging in posterior cortical atrophy..  Journal of neurology.  262:1483-92. 2015
90. Use of the MoCA in Detecting Early Alzheimer's Disease in a Spanish-Speaking Population with Varied Levels of Education..  Dementia and geriatric cognitive disorders extra.  5:85-95. 2015
91. Manual segmentation qualification platform for the EADC-ADNI harmonized protocol for hippocampal segmentation project..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  11:161-74. 2015
92. Rarity of the Alzheimer disease-protective APP A673T variant in the United States..  JAMA neurology.  72:209-16. 2015
93. Comparing 3T and 1.5T MRI for mapping hippocampal atrophy in the Alzheimer's Disease Neuroimaging Initiative..  AJNR. American journal of neuroradiology.  36:653-60. 2015
94. Relationship between hippocampal atrophy and neuropathology markers: a 7T MRI validation study of the EADC-ADNI Harmonized Hippocampal Segmentation Protocol..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  11:139-50. 2015
95. Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures..  Neurology.  84:729-37. 2015
96. Low plasma ApoE levels are associated with smaller hippocampal size in the Alzheimer's disease neuroimaging initiative cohort..  Dementia and geriatric cognitive disorders.  39:154-66. 2014
97. Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study..  JAMA neurology.  71:1394-404. 2014
98. The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  11:111-25. 2014
99. Harmonized benchmark labels of the hippocampus on magnetic resonance: the EADC-ADNI project..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  11:151-60.e5. 2014
100. Delphi definition of the EADC-ADNI Harmonized Protocol for hippocampal segmentation on magnetic resonance..  Alzheimer's & dementia : the journal of the Alzheimer's Association.  11:126-38. 2014
101. Age effects on cortical thickness in cognitively normal elderly individuals..  Dementia and geriatric cognitive disorders extra.  4:221-7. 2014
102. The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data..  Brain imaging and behavior.  8:153-82. 2014
103. The "Alzheimer's type" profile of semantic clustering in amnestic mild cognitive impairment..  Journal of the International Neuropsychological Society : JINS.  20:402-12. 2014
104. Risk factors for behavioral abnormalities in mild cognitive impairment and mild Alzheimer's disease..  Dementia and geriatric cognitive disorders.  37:315-26. 2014
105. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease..  NeuroImage. Clinical.  461-72. 2014
106. Establishing magnetic resonance images orientation for the EADC-ADNI manual hippocampal segmentation protocol..  Journal of neuroimaging : official journal of the American Society of Neuroimaging.  24:509-14. 2013
107. Reliability of two-dimensional and three-dimensional pseudo-continuous arterial spin labeling perfusion MRI in elderly populations: comparison with 15O-water positron emission tomography..  Journal of magnetic resonance imaging : JMRI.  39:931-9. 2013
108. Alzheimer disease: 'generation next' in Alzheimer disease genetic studies..  Nature reviews. Neurology.  9:422-3. 2013
109. Multilocus genetic profiling to empower drug trials and predict brain atrophy..  NeuroImage. Clinical.  827-35. 2013
110. Similar verbal fluency patterns in amnestic mild cognitive impairment and Alzheimer's disease..  Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.  28:400-10. 2013
111. Cerebrospinal fluid Aβ levels correlate with structural brain changes in Parkinson's disease..  Movement disorders : official journal of the Movement Disorder Society.  28:302-10. 2013
112. Cortical thickness and semantic fluency in Alzheimer's disease and mild cognitive impairment..  American journal of Alzheimer's disease (Columbia, Mo.).  1:81-92. 2013
113. Mapping cortical atrophy in Parkinson's disease patients with dementia..  Journal of Parkinson's disease.  3:69-76. 2013
114. Ventricular enlargement and its clinical correlates in the imaging cohort from the ADCS MCI donepezil/vitamin E study..  Alzheimer disease and associated disorders.  27:174-81. 2013
115. Verbal memory is associated with structural hippocampal changes in newly diagnosed Parkinson's disease..  Journal of neurology, neurosurgery, and psychiatry.  84:23-8. 2012
116. Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study..  Alzheimer's research & therapy.  4:-. 2012
117. Regional brain volume differences in symptomatic and presymptomatic carriers of familial Alzheimer's disease mutations..  Journal of neurology, neurosurgery, and psychiatry.  84:154-62. 2012
118. Comparing hippocampal atrophy in Alzheimer's dementia and dementia with lewy bodies..  Dementia and geriatric cognitive disorders.  34:44-50. 2012
119. Agitation and psychosis associated with dementia with lewy bodies exacerbated by modafinil use..  American journal of Alzheimer's disease and other dementias.  27:468-73. 2012
120. Novel late-onset Alzheimer disease loci variants associate with brain gene expression..  Neurology.  79:221-8. 2012
121. Identification of common variants associated with human hippocampal and intracranial volumes..  Nature genetics.  44:552-61. 2012
122. Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative..  Neurobiology of aging.  34:62-72. 2012
123. Hippocampal atrophy and ventricular enlargement in normal aging, mild cognitive impairment (MCI), and Alzheimer Disease..  Alzheimer disease and associated disorders.  26:17-27. 2012
124. Cortical and hippocampal atrophy in patients with autosomal dominant familial Alzheimer's disease..  Dementia and geriatric cognitive disorders.  32:118-25. 2011
125. Hippocampal and ventricular changes in Parkinson's disease mild cognitive impairment..  Neurobiology of aging.  33:2113-24. 2011
126. Biochemical, neuropathological, and neuroimaging characteristics of early-onset Alzheimer's disease due to a novel PSEN1 mutation..  Neuroscience letters.  487:287-92. 2010
127. Effects of ApoE4 and maternal history of dementia on hippocampal atrophy..  Neurobiology of aging.  33:856-66. 2010
128. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects..  Neurobiology of aging.  31:1284-303. 2010
129. 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI..  Human brain mapping.  31:786-97. 2010
130. Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia..  Movement disorders : official journal of the Movement Disorder Society.  25:687-95. 2010
131. Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects..  NeuroImage.  51:488-99. 2010
132. Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls..  Human brain mapping.  30:2766-88. 2009
133. Surface feature-guided mapping of cerebral metabolic changes in cognitively normal and mildly impaired elderly..  Molecular imaging and biology.  12:218-24. 2009
134. Comparison of AdaBoost and support vector machines for detecting Alzheimer's disease through automated hippocampal segmentation..  IEEE transactions on medical imaging.  29:30-43. 2009
135. Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls..  NeuroImage.  45:S3-15. 2008
136. Use of magnetic resonance imaging to identify mild cognitive impairment: who should be imaged?.  CNS spectrums.  13:18-20. 2008
137. Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal..  Neurobiology of aging.  31:1077-88. 2008
138. Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls..  NeuroImage.  43:59-68. 2008
139. Automatic subcortical segmentation using a contextual model..  Medical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention.  11:194-201. 2008
140. Mapping progressive brain structural changes in early Alzheimer's disease and mild cognitive impairment..  Neuropsychologia.  46:1597-612. 2007
141. Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature..  Dementia and geriatric cognitive disorders.  25:115-26. 2007
142. Computational anatomical methods as applied to ageing and dementia..  The British journal of radiology.  S78-91. 2007
143. Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease..  Archives of neurology.  64:1489-95. 2007
144. Brain mapping as a tool to study neurodegeneration..  Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.  4:387-400. 2007
145. Structural correlates of apathy in Alzheimer's disease..  Dementia and geriatric cognitive disorders.  24:91-7. 2007
146. Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations..  Brain : a journal of neurology.  130:1767-76. 2007
147. 3D mapping of language networks in clinical and pre-clinical Alzheimer's disease..  Brain and language.  104:33-41. 2007
148. 3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease..  Brain : a journal of neurology.  129:2867-73. 2006
149. Early diagnostics and therapeutics for Alzheimer's disease--how early can we get there?.  Expert review of neurotherapeutics.  6:1293-306. 2006
150. Multiple system atrophy presenting with language impairment..  Neurology.  67:726-7. 2006
151. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps..  Archives of neurology.  63:693-9. 2006
152. 3D mapping of mini-mental state examination performance in clinical and preclinical Alzheimer disease..  Alzheimer disease and associated disorders.  20:224-31. 2006
153. Disseminated Pseudallescheria boydii infection successfully treated with voriconazole..  Journal of neurology, neurosurgery, and psychiatry.  76:1741-2. 2005
154. Deep white matter pathologic features in watershed regions: a novel pattern of central nervous system involvement in MELAS..  Archives of neurology.  62:1154-6. 2005